J. Lis, Co- Author of ISPOR Taxonomy of Patient Registries: Classification, Characteristics

J. Lis, Co- Author of ISPOR Taxonomy of Patient Registries: Classification, Characteristics

SELECTEDPUBLICATIONS
Joanna Lis
(May 2013)
  1. J. Lis, co- author of “ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms.” Polygenis D, ed. Lawrenceville, NJ; 2013.
  2. J. Lis, M. Głasek, P. Kawalec, “Economic evaluation of acute lymphoblastic leukemia treatment of pediatric and adolescent patients with clofarabine (Evoltra) in combination with chemotherapy in Poland”, Journal of Health Policy & Outcomes Research, 2/2012
  3. D. Golicki, M. Niewada, J. Lis, K. Pol, T. Hermanowski, M. Tłustochowicz, „Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomised trials”, Polish Archives of Internal Medicine (listed in PubMed), ISSN: 1897-9483, 11 Jan 2012
  4. BOOK under red.: W. Kalbarczyk, K. Łanda, et all, J. Lis author of book chapter in “Health insurance policy and benefit baskets: overview of the solutions”, Krakow/Warsaw, 2011, IABN 978-83-928556-1-1
  5. K. Kostrzewska, J. Lis, et all “Cost-Utility of Amisulpride Compared with First Generation Antipsychotics in Treatment of Schizophrenia in Poland”, Value in Health, Volume 14, Issue 7 , Page A292, November 2011
  6. P. Wojciechowski, A. Stozek, A. Machowska, M. Gaweska, J. Lis, at all, “Comparative Efficacy of Maintenance of Sinus Rhythm Versus Rate Control Strategies in the Treatment of Atrial Fibrillation – Systematic Review and Meta-Analyses”, Value in Health, Volume 14, Issue 7, Page A364, November 2011.
  7. Marco Barbieri, Michael Drummond, Frans Rutten, John Cook, Henry A. Glick, Joanna Lis at all “What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?”Value in Health Vol. 13, Issue 8, Pages 1028-1037, 2010
  8. B. Gwiosda at all, J. Lis, BUDGET IMPACT ANALYSIS OF DRONEDARONE IN TREATMENT OF NON-PERMANENT ATRIAL FIBRILLATION (AF) IN POLAND, ISPOR conference,Value in Health 2010
  9. D. Szmurlo, B. Gwiosda, M. Wladysiuk, J. Lis,M. Glasek, R. Plisko, “Cost-utility of dronedarone compared with amiodarone in treatment of atrial fibrillation in Poland “ISPOR 13th Annual European Congress,Value in Health 2010
  10. D. Wilk, J. Rutkowski, M.Dziewiątka, J. Lis et all „BUDGET IMPACT ANALYSIS OF AMISULPRIDE IN TREATMENT OF SCHIZOPHRENIA IN POLAND” ISPOR 13th Annual European Congress, Value in Health 2010
  11. J. Rutkowski, Ł. Deryło, M. Fedyna, J. Lis et all „ COST-EFFECTIVENESS OF LENOGRASTIM NEUTROPENIA DURATION IN CHILDREN RECEIVING CHEMOTHERAPY FOR LEUKEMIA” ISPOR 15th Annual International Meeting, Atlanta, 15-19May2010
  12. G. Nogas, at all J. Lis, „ECONOMIC ANALYSIS OF ENOXAPARIN IN COMPARISON WITH FONDAPARINUX IN THE TREATMENT OF DEEP-VEIN THROMBOSIS (DVT):, ISPOR 15th Annual International Meeting, Atlanta, 15-19 May 2010
  13. J. Rutkowski, Ł. Deryło, M. Fedyna, R. Plisko, J. Lis, M. Władysiuk ‘ „Cost-effectiveness of Lenograstim on Neutropenia duration in adults receiving chemotherapy for solid tumors or lymphomas”, ISPOR 15th Annual International Meeting, Atlanta, 15-19 May 2010
  14. Drummond M, Barbieri M, Cook J, et al. (J. LIS) “Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report”. Value in Health Vol. 12, Issue 4, Pages 409-418, 2009
  15. BOOK: Wendykowska K, Lis J, Adamski J, at all. (red. K. Łanda),“Pricing: pharmaceuticals’ prices, negotiations and risk sharing agreements” ISBN 978-83-928558-0-4, Krakow/Warsaw 2009
  16. Walczak J. , DardzińskiW. , Kusy M. , Lis J. , Nogas G.’”THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND”, International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, 8-11 November 2008.
  17. Rys P, Kucia K, Pankiewicz O, Rogoz A, Lis J at al, „LEFLUNOMIDE IN RHEUMATOID ARTHRITIS A COMPARISON OF EFFICACY AND SAFETY OF LEFLUNOMIDE WITH BIOLOGIC DRUGS IN THE TREATMENT OF RHEUMATOID ARTHRITIS”, International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, 8-11 November 2008
  18. McEwan P, Woehl A, Kawalec P, Lis J, Walczak J., “COST-UTILITY OF INSULIN GLARGINE COMPARED TO PREMIX IN TYPE 2 DIABETES MELLITUS FROM A PUBLIC PAYER PERSPECTIVE IN POLAND” International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, 8-11 November 2008
  19. McEwan P, Woehl A, Kawalec P, Lis J, Walczak J, „COST-UTILITY OF INSULIN GLARGINE COMPARED TO NPH IN TYPE 1 DIABETES MELLITUS FROM PUBLIC PAYER PERSPECTIVE IN POLAND” International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, 8-11 November 2008
  20. Walczak J. , Gebus E. , Lasota K. , Semeniuk A. , Pawlik D. , Malczak I. , Lis J. , “COST-UTILITY ANALYSIS OF DOCETAXEL VERSUS STANDARD REGIMEN IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER IN POLAND” International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, 8-11 November 2008
  21. Kawalec P, Lis J, Glasek M, „COST-EFFECTIVENESS ANDCOST‑UTILITY ANALYSISOF TRITACE COMB® (RAMIPRIL/HCTZ)IN THE TREATMENT OF HYPERTENSION IN POLAND”, International Society for Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, 8-11 November 2008
  22. J.Lis, M. Głasek, ”Strengths and weaknesses of health systems and reimbursement in the EU - evaluation of micro-and macro-economic " chapter in BOOK: Health Care and Economy: the public sector and the market”, Warsaw University, (ISBN 978-83-89069-75-7), 2007
  23. Golicki D, Niewada M, Lis J, Kaminski B, Jakubczyk M, Macioch T, „LEFLUNOMID VERSUS CYCLOSPORIN IN METHOTREXATE-RESISTANT RHEUMATOID ARTHRITIS IN POLAND: A COST-EFFECTIVENESS ANALYSIS “, ISPOR 10thAnnual European Congress, Dublin, Ireland, 20-23 October 2007
  24. Kowalik E, Jakubczyk M, Lis J, Niewada M, „COST-EFFECTIVENESS OF AMISULPRID COMPARED TO RISPERIDONE AND OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN POLAND”, ISPOR 9thAnnual European Congress, Copenhagen, Denmark, 28-31 October 2006
  25. Kawalec P, Lis J, “COST MINIMALISATION ANALYSIS OF AVERAGE ACUTE HOSPITAL INFECTIONS TREATMENT WITH TARGOCID (TEICOPLANIN) OR VANCOMYCINE FROM SERVICE-PROVIDER PERSPECTIVE IN POLAND, ISPOR 9thAnnual European Congress, Copenhagen, Denmark, 28-31 October 2006
  26. J.Lis, M.Głasek, “The effects of reduction of drug consumption costs in the EU “in BOOK: Health Care and Economy: management dilemmas, Warsaw University, ISBN 83-89069-88-1, 2006
  27. Z. Skrzypczak, J.Lis, K. Piotrowski, „The pharmaceutical market in Poland after its accession to the European Union", in BOOK: Management Dilemmas, Department of Management, Warsaw University, ISSN 1644-9584, 3/2005 (9)
  28. Orlewska E, Lis J, “TREATMENT PATTERN, RESOURCE UTILIZATION AND COSTS OF INPATIENT THROMBOPROPHYLAXIS IN POLAND”, ISPOR 8th Annual European Congress 6-8 November 2005, Florence, Italy
  29. Orlewska E, Lis J, Gierczynski J, „THE COST-EFFECTIVENESS OF RISENDRONATE COMPARED TO ALENDRONATE IN POST-MENOPAUSAL WOMEN WITH ESTABLISHED OSTEOPOROSIS: A POLISH ANALYSIS”, ISPOR 8th Annual European Congress 6-8 November 2005, Florence, Italy
  30. Kamiński B, Niewada M, Latek M, Lis J, Gierczynski J „THE ESTIMATION OF POTENTIAL BUDGETARY IMPACT OF INSULIN GLARGINE IN POLISH SETTINGS” ISPOR 8th Annual European Congress 6-8 November 2005, Florence, Italy
  31. Kawalec P, Lis J, Gierczynski J, “COST OF COMMUNITY ACQUIRED PNEUMONIA (CAP) TREATMENT WITH KETEK (TELITHROMYCIN) VS CLARITHROMYCIN FROM PUBLIC PAYER PERSPECTIVE IN POLAND”, ISPOR 8th Annual European Congress 6-8 November 2005, Florence, Italy
  32. Lis J. “Statistics in Health Economics” in BOOK „PHARMACOECONOMICS: economical evaluation of health care programs” eds., Warsaw University of Technology Publishing House, 2004
  33. Lis J „Economic analysis in healthcare–cost cutting or increasing profitability?” - chapter in BOOK: Management Aspects: HEALTH CARE , 4/2004, Warsaw University 4/2004 )
  34. M Jakubczyk; E Kowalik; M Niewada; A Kubler; J Lis; B Kamiński „Assessing the cost-effectiveness of drotrecogin alfa (activated) in severe sepsis in Poland” Value in Health, vol 7, no 6, 2004
  35. A Kubler; E Kowalik; M Niewada; J Lis; M Jakubczyk „The costs of severe sepsis management in intensive care units in Poland”, Value in Health, vol 7, no 6, 2004
  36. E Orlewska, J. Lis „Health Effects And Health Care Resource Utilization In Polish Schizophrenic Outpatients Initiating Or Changing To Olanzapine Or Typical Antipsychotic Monotherapy: Analysis of 12-month Data From Soho Study”, Value in Health, vol 7, no 6, 2004
  1. Lis J, Orlewska E, Frey J „ Basics pharmacoeconomics”, Urological Journal Review. 5/3 (25); 2004: 23-26 (Podstawy farmakoekonomiki. Przegląd Urologiczny 5/3 (25); 2004: 23-26)
  1. Taton J. Lis J. Mozejko-Pastewka B. Czech A. Frey J. Haczynski J. Intensive insulin therapy in patients with type 2 diabetes mellitus after myocardial infarction - Cost-effectiveness analysis with the stochastic method. Diabetologia Polska. Vol. 11(2)(pp 115-124), 2004
  1. Meder J, Dębowska G, Lis J, Araszkiewicz A, Sierosławska K, Kolesaric A, Treuer T, “Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6-month efficacy and tolerability results (The Intercontinental Schizophrenia Outpatient Health Outcomes – IC-SOHO “ in Psychiatria Polska, 2004, tom XXXVIII, nr 3, pp.469-484
  1. Orlewska E, Krzakowski M, Lis J, “Cost-effectiveness analysis of gemcitabine in combination with cisplatin versus novel combination chemotherapies in the treatment of nonsmall cell lung cancer in Poland.”, Value in Health, nr, 2003
  1. Tilden D, Lis J, Stynes, Aristides “The cost of Gemzar/cisplatin compared with other novel chemotherapeutic agents in Poland” Value in Health, 2003
  1. Dębowska G, Meder J, Lis J, Szulc A. “Extrapyramidal Symptoms Among Patients with Schizophrenia Treated with Olanzapine or Other Antipsychotics: 6-month Results of the in the Intercontinental Schizophrenia Outpatient Health Outcomes study - IC-SOHO (Polish Sample)” , ICN Conference, 2004
  1. Dębowska, J. Meder, J. Lis, Tamas Treuer “ “ Comparison of olanzapine, risperidone and typical antipsychotic treatment in patients with schizophrenia from Central Eastern Europe participating in observational study IC-SOHO - 12 months results”, poster on Polish Psychiatric Association meeting, 2004
  2. E. Orlewska, M. Krzakowski, J. Lis, „Cost-effectiveness analysis of gemcitabine in combination with cisplatin versus novel combination chemotherapies in the treatment of non small lung cancer in Poland” – Brussels, EORTC, 2003
  3. E. Orlewska, J. Lis“Cost-effectiveness of various treatment strategies in postmenopausal women with osteoporosis in Poland”, FARMAKOEKONOMIKA 1/2002
  4. E. Orlewska, J. Lis“Cost-Effectiveness analysis of Evista”, ISPOR Washington, May 2002
  5. J. Jassem et al (J. Lis) “A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life” LUNG CANCER, 2002
  6. P. Radziwiłłowicz, W. Radziwiłłowicz, J.Lis, “Effect of olanzapine treatment on cognitive functions in patients with schizophrenia”, Psychiatria Polska, 2002
  7. J. Lis, E. Orlewska “Modeled cost-effectiveness and cost –utility analysis of various treatment strategies in Polish osteoporotic postmenopausal women without previous vertebral fractures”, THIRD INTERNATIONAL SYMPOSIUM ON CLINICAL AND ECONOMIC ASPECTS OF OSTEOPOROSIS AND OSTEOARTHRITIS, Barcelona Nov 2002
  8. J. Lis, A.E. Eiben “A multi-sexual genetic algorithm for multiobjective optimization” in IEEE International Conference on Evolutionary Computation, pp. 59-64, Indianapolis, US, 1997
  9. J. Lis “Feature selection by genetic algorithm” 4th European Conference on Engineering &Medicine, Warsaw, 1997
  10. J. Lis, Rembiecha A, “The log hyperbolic distribution fitting by genetic algorithm with the dynamic probability of mutation”, Fifth Annual Conference on Evolutionary Programming, San Diego, 1996
  11. J. Lis “Parallel genetic algorithm with dynamic control parameters” IEEE International Conference on Evolutionary Computation, 324-330, Nagoya, Japan, 1996
  12. J. Lis “Self-adapting parallel genetic algorithm with the dynamic mutation probability, crossover rate and population size” in Proc. Of the First National Conference on Evolutionary Algorithms, Zakopane, pp. 79-86, June 1996
  13. J. Lis “The support of medical diagnosis applying genetic algorithms” in Proc. 3-rd European Conference on Engineering and Medicine, Florencja, Apr 30- May 3, 1995
  14. J. Lis “The synthesis of the ranked neural networks applying genetic algorithms with the dynamic probability of mutation”, in J. Mira, F, Sandoval eds. “FROM NATURAL TI ARTIFICIAL NEURAL COMPUTATION” Lecture Notes in Computer Science 930, pp. 498-504, Springer-Verlag, 1995
  15. J. Lis “Genetic algorithm with the dynamic probability of mutation in the classification problem” PATTERN RECOGNITION LETTERS, vol. 16, 1311-1321, North-Holland, 1995
  16. J. Lis “Genetic algorithm with dynamic probability mutation and cross-over in the formal neuron learning” Second European Congress on Intelligent Technologies and Soft Computing – EUFIT’95, Aachen, Germany, August 19-21, 1995
  17. J. Lis “Algorithms of classifiers design based on neural networks” PhD Thesis, Institute of Biocybernetics and Biomedical Engineering PAS, Warsaw, 1994
  18. J. Lis “c-Means clustering with the Lp norms and its applications”, Biocybernetics and Biomedical Engineering vol. 13, no1-4, Warsaw, 1993

1 | Page

Top View